文献速递脊柱关节炎

RORγt抑制通过主要调节γδ-T细胞改善IL-23驱动的实验性银屑病关节炎

RORγt inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating γδ-T cells.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

在B10.RIII小鼠经流体动力学注射IL-23增强型游离体载体(IL-23 EEV)系统性过表达IL-23的银屑病关节炎模型中,RORγt拮抗剂显著改善银屑病、外周关节炎和结肠炎临床评分,减轻炎症诱导的骨丢失与骨侵蚀,并抑制γδ-T细胞和Th17细胞的17型细胞因子应答。

要点

  • RORγt阻断使IL-23 EEV小鼠银屑病、外周关节炎和结肠炎临床评分分别改善91.8%、58.2%和7.0%(P < 0.001)。
  • RORγt阻断减轻炎症诱导的骨丢失和骨侵蚀(跟骨P < 0.05,胫骨P < 0.01)。
  • γδ-T细胞是T细胞来源IL-17A和IL-22的主要来源,RORγt抑制显著减少γδ-T细胞和Th17细胞(P < 0.001)。

核心结论

  • RORγt阻断在临床前PsA模型中显示治疗疗效,并对肌肉骨骼外表现有保护作用,反映为γδ-T细胞和Th17细胞的17型细胞因子应答明显减弱。

研究设计与样本

  • 在B10.RIII小鼠中通过流体动力学注射IL-23增强型游离体载体(IL-23 EEV)系统性过表达IL-23,评估RORγt拮抗剂对合并皮肤、关节和肠道炎症的疗效。

主要发现

  • RORγt阻断显著改善IL-23 EEV小鼠的银屑病、外周关节炎和结肠炎(临床评分和体重丢失分别改善91.8%、58.2%和7.0%,P < 0.001)。
  • RORγt阻断减轻炎症诱导的骨丢失和骨侵蚀(跟骨P < 0.05,胫骨P < 0.01)。
  • 持续IL-23过表达仅导致轻度骶髂关节炎表现。
  • γδ-T细胞在IL-23过表达期间扩增,RORγt抑制显著减少γδ-T细胞和Th17细胞(P < 0.001)。

关键数值与推荐

  • RORγt阻断使银屑病、外周关节炎和结肠炎临床评分分别改善91.8%、58.2%和7.0%(P < 0.001)。
  • RORγt阻断使跟骨骨侵蚀减少(P < 0.05)、胫骨骨侵蚀减少(P < 0.01)。
  • RORγt抑制减少γδ-T细胞和Th17细胞(P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Divergent therapeutic outcomes on different disease domains have been noted with IL-23 and IL-17A-blockade in PsA. Therefore, elucidating the role of RORγt, the master regulator of type 17 immune responses, is of potential therapeutic interest. To this end, RORγt inhibition was assessed in combined skin, joint and gut inflammation in vivo, using a PsA model. METHODS: We tested the efficacy of a RORγt antagonist in B10.RIII mice challenged with systemic overexpression of IL-23 by hydrodynamic injection of IL-23 enhanced episomal vector (IL-23 EEV). Clinical outcomes were evaluated by histopathology. Bone density and surface erosions were examined using micro-computed tomography. Cytokine production was measured in serum and by intracellular flow cytometry. Gene expression in PsA-related tissues was analysed by qPCR. RESULTS: RORγt-blockade significantly ameliorated psoriasis, peripheral arthritis and colitis development in IL-23 EEV mice (improvement of clinical scores and weight loss respectively by 91.8%, 58.2% and 7.0%, P < 0.001), in line with profound suppression of an enhanced type IL-17 immune signature in PsA-affected tissues. Moreover, inflammation-induced bone loss and bone erosions were reduced (P < 0.05 in calcaneus, P < 0.01 in tibia). Sustained IL-23 overexpression resulted in only mild signs of sacroiliitis. Gamma-delta (γδ)-T cells, the dominant source of T cell-derived IL-17A and IL-22, were expanded during IL-23 overexpression, and together with Th17 cells, clearly countered by RORγt inhibition (P < 0.001). CONCLUSION: RORγt-blockade shows therapeutic efficacy in a preclinical PsA model with protection towards extra-musculoskeletal manifestations, reflected by a clear attenuation of type 17 cytokine responses by γδ-T cells and Th17 cells.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Mortier C, Gracey E, Coudenys J, et al. RORγt inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating γδ-T cells. Rheumatology (Oxford). 2023. PMID: 36661300. doi:10.1093/rheumatology/kead022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。